Fox Run Management L.L.C. Purchases New Shares in Nektar Therapeutics $NKTR

Fox Run Management L.L.C. purchased a new stake in Nektar Therapeutics (NASDAQ:NKTR) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 26,522 shares of the biopharmaceutical company’s stock, valued at approximately $1,121,000. Fox Run Management L.L.C. owned approximately 0.13% of Nektar Therapeutics as of its most recent SEC filing.

Other large investors have also bought and sold shares of the company. BNP Paribas Financial Markets boosted its position in Nektar Therapeutics by 93.8% during the 3rd quarter. BNP Paribas Financial Markets now owns 434 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 210 shares in the last quarter. Compass Wealth Management LLC bought a new stake in Nektar Therapeutics during the 3rd quarter valued at approximately $88,000. Bessemer Group Inc. boosted its position in Nektar Therapeutics by 1,741.2% during the 3rd quarter. Bessemer Group Inc. now owns 1,565 shares of the biopharmaceutical company’s stock valued at $90,000 after acquiring an additional 1,480 shares in the last quarter. Flagship Harbor Advisors LLC bought a new stake in Nektar Therapeutics during the 4th quarter valued at approximately $92,000. Finally, Headlands Technologies LLC bought a new stake in Nektar Therapeutics during the 2nd quarter valued at approximately $65,000. 75.88% of the stock is owned by institutional investors.

Nektar Therapeutics Stock Down 0.7%

Shares of NKTR opened at $56.23 on Wednesday. The business’s 50 day moving average price is $75.34 and its 200-day moving average price is $62.19. Nektar Therapeutics has a 52 week low of $7.99 and a 52 week high of $109.00. The stock has a market cap of $1.90 billion, a P/E ratio of -6.68 and a beta of 1.13.

Nektar Therapeutics (NASDAQ:NKTR) last issued its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported ($1.82) EPS for the quarter, missing analysts’ consensus estimates of ($1.58) by ($0.24). Nektar Therapeutics had a negative return on equity of 85.40% and a negative net margin of 284.18%.The company had revenue of $10.86 million during the quarter, compared to the consensus estimate of $10.69 million. On average, equities analysts anticipate that Nektar Therapeutics will post -9.45 EPS for the current year.

Insider Activity at Nektar Therapeutics

In other news, CEO Howard W. Robin sold 444 shares of the business’s stock in a transaction that occurred on Tuesday, May 19th. The stock was sold at an average price of $65.51, for a total value of $29,086.44. Following the sale, the chief executive officer directly owned 75,045 shares of the company’s stock, valued at $4,916,197.95. The trade was a 0.59% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 2.50% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

NKTR has been the topic of several research reports. TD Cowen initiated coverage on Nektar Therapeutics in a research report on Tuesday, March 17th. They set a “buy” rating on the stock. Wall Street Zen raised Nektar Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday, May 17th. Wedbush cut their price objective on Nektar Therapeutics from $95.00 to $80.00 and set a “neutral” rating on the stock in a research report on Monday, May 11th. Jefferies Financial Group reaffirmed a “buy” rating on shares of Nektar Therapeutics in a research report on Wednesday, April 22nd. Finally, BTIG Research lifted their price objective on Nektar Therapeutics from $151.00 to $178.00 and gave the company a “buy” rating in a research report on Monday, April 20th. Nine research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $149.63.

Nektar Therapeutics Company Profile

Nektar Therapeutics (NASDAQ:NKTR) is a biopharmaceutical company dedicated to discovering and developing novel drug candidates through its proprietary chemistry and immunology platforms. The company focuses on polymer conjugate technology, which enables the creation of longer-acting versions of existing drugs, and on T-cell modulatory therapies aimed at harnessing the body’s immune system to treat cancer and other serious diseases.

Nektar’s product portfolio and pipeline include a range of clinical-stage and partnered programs.